Bone marrow engraftment in a rodent model of chemical carcinogenesis but no role in the histogenesis of hepatocellular carcinoma

H Ishikawa, K Nakao, K Matsumoto, D Nishimura, T Ichikawa, K Hamasaki, K Eguchi

Background and aim: Recent studies indicated that hepatic stem cells in the bone marrow could differentiate into mature hepatocytes, suggesting that bone marrow cells could be used for replacement of damaged hepatocytes in a variety of liver diseases. Hepatocellular carcinoma (HCC) is thought to arise from hepatic stem cells. In this study, we investigated the malignant potential of hepatic stem cells derived from the bone marrow in a mouse model of chemical hepatocarcinogenesis.

Methods: Bone marrow cells were obtained from the male β-galactosidase (β-gal) transgenic mouse and transplanted into female recipient mice. Hepatocarcinogenesis was induced by a year of treatment with diethylnitrosamine and phenobarbital (NDEA/PB). One year later, the liver was removed from each treated mouse and evaluated by x-gal staining, immunohistochemistry, and fluorescence in situ hybridisation (FISH).

Results: Forty per cent of recipient mice survived and developed multiple HCC. Clusters of β-gal positive mature hepatocytes were detected sporadically in the entire liver of NDEA/PB treated mice who underwent bone marrow transplantation (BMT) with while no such hepatocytes were identified in the liver of BMT mice that were not treated with NDEA/PB. The Y chromosome was detected with the same frequency as the donor male liver in clusters of β-gal positive mature hepatocytes by FISH. However, no HCC was positive for β-gal or the Y chromosome. Immunohistochemically, β-gal positive mature hepatocytes did not express CD34 or α-fetoprotein.

Conclusions: Our results suggest that hepatic stem cells derived from the bone marrow have low malignant potential, at least in our model.

Although patients at high risk of hepatocellular carcinoma (HCC) are well defined in the clinical setting, the process of hepatocarcinogenesis is not well understood. Hepatitis B or C virus can induce chronic hepatitis and potentially results in liver cirrhosis and HCC, and patients with these viral infections are the most frequent among HCC patients. However, the consequences of viral infection in the process of hepatocarcinogenesis are not clearly understood. In this regard, the original cell that develops into a cancerous cell in HCC is debated. Two cell lineages have been considered as candidates: the first is the hepatic stem cell and the second is the mature hepatocyte. However, there is no clear evidence on which cell is directly involved in the development of HCC.

Extensive studies have been conducted on the hepatic stem cell but the results are controversial. Several candidate hepatic stem cells have been described in a rodent experimental model (including oval cells, liver epithelial cells, and small hepatocytes). Previous studies indicated that bone marrow cells can differentiate into oval cells in rodents and that a similar process could possibly take place in humans. If this scenario is correct, isolation of hepatic stem cells from bone marrow cells could be a valuable strategy for future replacement therapy of damaged or malfunctioned hepatocytes. However, the safety and efficacy of hepatic stem cells derived from bone marrow cells should be adequately confirmed before any such therapies are tested in humans.

In an attempt to assess hepatic stem cells, in the present study we investigated the malignant potential of hepatic stem cells derived from bone marrow in vivo. To identify hepatic stem cells, bone marrow cells of β-galactosidase (β-gal) transgenic male mice were transplanted into recipient female mice. After bone marrow transplantation (BMT), HCC was induced in the recipients by chemical hepatocarcinogenic compounds and the presence of β-gal and the Y chromosome was evaluated in HCC.

MATERIALS AND METHODS
Bone marrow transplantation
Six week old male B6-129S-Gtrosa and female B6-129-F2 mice were purchased from Jackson Laboratory (Bar Habor, Maine, USA). B6-129S-Gtrosa mice express transgenic β-gal in the whole body and B6-129-F2 mice are the parental strain of B6-129S-Gtrosa. Animal experiments were performed in accordance with institutional guidelines, and the study was approved by the ethics committee of Nagasaki University. BMT was performed as reported previously. Briefly, the thigh was removed from a dead male B6-129S-Gtrosa, and bone marrow cells were harvested and suspended in phosphate buffered saline at a density of 1×10⁶ cells/ml. Female B6-129-F2 mice were irradiated sublethally and 5×10⁶ of the above bone marrow cells were injected via the tail vein. To confirm successful transplantation of donor bone marrow cells, a sample of recipient bone marrow cells was obtained from B6-129-F2 mice after sacrifice and examined for x-gal staining.

Abbreviations: AFP, α-fetoprotein; β-gal, β-galactosidase; BMT, bone marrow transplantation; FISH, fluorescence in situ hybridisation; HCC, hepatocellular carcinoma; NDEA/PB, diethylnitrosamine/phenobarbital; H&E, haematoxylin-eosin

See end of article for authors’ affiliations

Correspondence to: Professor K Eguchi, The First Department of Internal Medicine, Nagasaki University of Medicine, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan; joco@venus.dti.ne.jp

Accepted for publication 14 December 2003

Bone marrow cell and hepatic carcinogenesis

Chemically induced hepatocarcinogenesis

To induce HCC, two weeks after BMT, 80 mg/l diethylnitrosamine (NDEA; Sigma, St Louis, Missouri, USA) was added to the drinking water of B6-129-F2 recipient mice for six weeks to initiate the process of hepatocarcinogenesis. This was followed by administration of 700 mg/l phenobarbital (PB; Wako, Tokyo, Japan) as a tumour promoting agent, until sacrifice. Ten bone marrow transplanted and 10 non-transplanted mice were each treated with NDEA/PB, and four mice who underwent BMT but not NDEA/PB treatment and four mice who received no treatment were maintained under the same conditions as controls.

X-gal staining

One year after the start of NDEA, mice who survived were sacrificed and the liver and bone marrow harvested. The liver was fixed in 10% formalin for 24 hours and paraffin embedded. Simultaneously, fresh frozen sections were also prepared. Routine histology was performed with haematoxylin-eosin (H&E) staining of both formalin fixed/paraffin embedded and fresh frozen sections. To identify bone marrow derived cells in the liver specimens, every fifth slide of 5 μm thick serial sections (total 125 slides) was stained for β-gal. X-gal staining kit (Gene Therapy Systems, San Diego, California, USA) was used with fresh frozen sections of the liver removed from each group according to the instructions provided by the manufacturer.

Immunohistochemistry

Immunohistochemistry was performed using antimouse CD34 or antimouse z-fetoprotein (AFP) antibody as the primary antibody. Tissue samples of the fresh frozen liver sections were cut into 5 μm thick sections and mounted on aminopropyltriethoxysilane coated glass slides. The streptavidin-biotin method (Histofine Staining Kit; Nichirei Company, Tokyo, Japan) was used for immunohistochemical detection, as described previously.13 X-gal and immunohistochemically treated slides were counterstained with haematoxylin. Numbers of clusters or cells positively stained in each section were counted and mean (SD) values were calculated for each sample.

Fluorescence in situ hybridisation

Because BMT was performed from male donor mice to female recipient mice, the transplanted bone marrow derived cells could be recognised in the recipient by the presence of the Y chromosome in the nucleus. Therefore, fluorescence in situ hybridisation (FISH) for the mouse Y chromosome was conducted to detect the transplanted bone marrow derived cells. Liver specimens of fresh frozen sections were pretreated using the Pretreatment Reagent Kit (Vysis, Downers Grove, Illinois, USA) according to the instructions supplied by the manufacturer, and hybridised with a mouse Y chromosome probe (Cambio, Cambridge, UK). Treated slides were observed under fluorescent microscopy.

RESULTS

X-gal staining and FISH of donor mice

In this study, we used the male B6-129S-Gtrosa mouse as a donor. It has been reported previously that this mouse expresses β-gal throughout the whole body.14 To confirm this, we performed x-gal staining and FISH for the Y chromosome in the liver. All hepatocytes were positive for x-gal staining (fig 1A) and 98% of bone marrow cells were x-gal stained (data not shown). FISH revealed that 28% of hepatocyte nuclei were positive for the Y chromosome (fig 1B). A positive FISH signal was detected in the nucleus which was confirmed by counterstaining with DAPI (fig 1B, inset). In addition, no nucleus showed two or more signals.

Survival rate

We first evaluated the survival rate of mice that underwent BMT and/or NDEA/PB treatment (table 1). All (100%, 4/4 each) control mice and mice that underwent BMT only were still alive at the end of the study. However, only five of 10 (50%) mice in the NDEA/PB treated group that did not undergo BMT were still alive at the end of the one year study period. The survival rate of mice subjected to BMT and NDEA/PB treatment was the lowest (4/10 mice, 40%).

Bone marrow transplantation

To confirm bone marrow replacement with β-gal gene transduced cells, bone marrow cells derived from each group of recipient mice were subjected to x-gal staining (fig 2A, 2B). Red blood cells were excluded by careful microscopic observation and only nuclear cells were examined. No x-gal stained bone marrow nuclear cells were found in mice that did not receive BMT. In contrast, 91–95% of bone marrow...
cells were x-gal stained in mice that received BMT with or without NDEA/PB treatment (table 1). These results indicated successful BMT in this study.

**Histopathological analysis of the liver of recipient mice**

NDEA/PB treatment resulted in the appearance of multiple macroscopic tumours in the liver after one year of treatment in both BMT and non-BMT mice (fig 2C, 2D). H&E stained sections of these tumours confirmed they were HCC (see fig 6A), based on the criteria defined previously. No other types of liver tumours, such as hepatoblastoma or cholangiocellular carcinoma, were noted in our experiment. Apart from HCC, abundant denatured hepatocytes, oval cells, cysts, and bile duct proliferation were observed in NDEA/PB treated mice compared with control livers.

**Phenotypic analysis by x-gal staining, immunohistochemistry, and FISH**

In a preliminary study, we sacrificed two BMT mice and liver samples were removed before NDEA/PB treatment. In these samples, β-gal positive hepatocytes were not identified (data not shown). Furthermore, no β-gal positive mature hepatocytes were detected in the livers of BMT mice that were not treated with NDEA/PB one year after BMT except for hematic cells in blood vessels (fig 3). However, x-gal staining of fresh frozen liver samples of four BMT mice treated with NDEA/PB showed sporadic clusters of β-gal positive mature hepatocytes (fig 4A, 4B). The number of these clusters in four mice was mean 0.18 (SD 0.10) in 53 (15) mm² sections (0.34 (0.10) cluster/mm², n = 125 slides). Furthermore, 17 (4.2) hepatocytes were present within the diameter of a cluster. Immunohistochemical analysis showed that β-gal positive

![Figure 2](image1.png)

**Figure 2** X-gal staining of bone marrow cells and hepatocellular carcinoma development in mice that underwent bone marrow transplantation (BMT) and diethylnitrosamine/phenobarbital (NDEA/PB) treatment. One year after the start of treatment, bone marrow cells were removed from each mouse and stained with x-gal. β-Gal positive cells appear as blue stained cells. Representative photographs are shown. (A) Bone marrow cells derived from a non-treated control mouse. (B) BMT and NDEA/PB treated mouse. (C) The liver removed from a non-treated control mouse. (D) BMT and NDEA/PB treated mouse (magnification A and B, ×200).

![Figure 3](image2.png)

**Figure 3** Haematoxylin-eosin (H&E) and x-gal stained liver section obtained from a mouse who underwent bone marrow transplantation (BMT) but not diethylnitrosamine/phenobarbital treatment. One year after BMT, the mouse was sacrificed and the liver removed and stained, as described in materials and methods. (A) H&E staining. (B) X-gal staining (magnification ×100).
Mature hepatocytes were negatively stained for CD34 and AFP (fig 5). In addition, FISH showed that β-gal positive mature hepatocytes were positive for the Y chromosome with the same frequency as the liver of donor male mice (26%, fig 4C). However, no HCC was positive for x-gal staining or FISH for the Y chromosome (fig 6, n = 10 tumours).

**DISCUSSION**

The liver is classified as a conditionally renewing tissue and under normal circumstances nearly all hepatocytes proliferate quiescently, with only 0.3–0.5% of cell showing active cell division.17 Under normal physiological conditions, there is no need for hepatic stem cells, and they only become evident on demand (for example, in circumstances associated with severe hepatic liver damage and coexistent impaired hepatocyte division). Previous studies demonstrated that oval cells, which are considered hepatic stem cells, appear after chemically induced liver injury.18 Although the oval cell clearly appears in such conditions, its precise origin and existence under normal conditions remains unclear. Recent studies reported that bone marrow cells could differentiate into oval cells.19 This finding indicates not only the origin of the oval cell but also the feasibility of in vivo labelling, at least in part, of oval cells.

In this study, we labelled bone marrow cells by β-gal staining. All hepatocytes were positive for β-gal in donor mice. Also, sensitivity of FISH for the Y chromosome was almost the same as that reported previously11 12 while this sensitivity was inadequate for the detection of donor cells. Thus we believe that our methods for tracing bone marrow cells of donor mice were acceptable in the present study.

After BMT, clusters of β-gal positive cells appeared only in BMT mice treated with NDEA/PB and not in BMT mice who did not receive NDEA/PB. These results suggest that in our
model, bone marrow cells can differentiate into mature hepatocytes under limited conditions. Bone marrow derived hepatic stem cells do not seem to be required for normal hepatocyte substitution. In addition, all hepatic stem cells derived from bone marrow cells may not have been labelled by this method and pre-existing hepatic stem cells, the origin of which is not clear, may be present in the liver. It has been reported that a stem cell of particular tissue can differentiate into another tissue. A stem cell network may exist in the whole body and involve each other in variant tissues. Recently, some investigators have reported that cell fusion between a hepatic lineage cell and a bone marrow cell was the source of bone marrow derived hepatocytes in the FAH−/− mouse model. However, other studies have shown that such fusion does not always play a role in haematopoietic to epithelial cell engraftment. Therefore, cell fusion may occur under specific conditions such as in the FAH−/− mouse model. Indeed, in the present study, we found that in β-gal positive hepatocytes, no nucleus had two or more Y chromosomes by FISH. This finding indicates that transdifferentiation, rather than cell fusion, was the main process in our model.

In this study, our interest was focused on the original cell lineage of HCC. Two major hypotheses (the “stem cell theory” and the “hepatocytic theory”) have been discussed for almost 20 years. Debate has centred on whether hepatocytes in dysplastic nodules are responsible for HCCs through a process of dedifferentiation and proliferation, or whether oval cells are the prime targets for malignant hepatocyte substitution. In addition, all hepatic stem cells with hepatic regeneration and carcinogenesis using other animal models or human studies.

Liver transplantation has already been introduced for the treatment of patients with chronic or acute hepatic failure and congenital or malignant liver disease, and a large proportion of such patients have previously been reported to benefit from this procedure. However, there are some problems with liver transplantation, including shortage of donors. Cell based therapy is being developed for replacement of damaged or malfunctioned hepatocytes. Bone marrow cells may potentially be used in cell based replacement therapy or gene delivery systems. Under these circumstances, our results indicate that stem cell therapy is safe.

ACKNOWLEDGMENTS

We thank Drs Tomoya Nishino and Masanobu Miyazaki of the Second Department of Internal Medicine, Nagasaki University School of Medicine, for technical advice on BMT. We thank Tomomi Kurashige and Yoko Iwasaki for skillful technical assistance.

Authors’ affiliations
H Ishikawa, K Matsumoto, D Nishimura, T Ichikawa, K Hamasaki, K Eguchi, The First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
K Nakao, Health Research Centre, Nagasaki University, Nagasaki, Japan

REFERENCES
1 Bergland EK. Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin Oncol 2001;28:321–31
Bone marrow cell and hepatic carcinogenesis